BioSante (BPAX), Teva (TEVA) Receive FDA Approval for Bio-T-Gel -Bloomberg
Tweet
Share
E-mail
Get Alerts BPAX Hot Sheet
Join SI Premium – FREE
Shares of BioSante Pharma (Nasdaq: BPAX) are rising after hours Tuesday following some Bloomberg headlines which suggest the company and Teva Pharma (Nasdaq: TEVA) have received FDA approval for Bio-T-Gel for men with low testosterone.
After closing at $0.761 this afternoon, shares are now trading around $0.855.
After closing at $0.761 this afternoon, shares are now trading around $0.855.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Milestone Pharmaceuticals starts Phase 3 AFib-RVR trial for etripamil
- FDA clears path for Protagenic's PT00114 anxiety drug IND submission
Create E-mail Alert Related Categories
FDA, RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
